Option Agreement, Covenant, Royalty Rate

No definition available.

Name:	amag_OptionAgreementCovenantRoyaltyRate
Namespace Prefix:	amag_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Payments due if the option to acquire the global rights to the Digoxin Immune Fab program is exercised, including the payment of the option exercise price and the regulatory milestone payments.

+ References

No definition available.

+ Details

Name:	amag_PaymentForExerciseOfOptionToAcquireGlobalRightsToDigoxinImmuneFabProgram
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payments Related to Collaborative Arrangement

+ References

No definition available.

+ Details

Name:	amag_PaymentsRelatedtoCollaborativeArrangement
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Possible Increase in Milestone Payment Amount, Percentage

+ References

No definition available.

+ Details

Name:	amag_PossibleIncreaseinMilestonePaymentAmountPercentage
Namespace Prefix:	amag_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Research And Development Asset Acquired Other Than Business Combination, Transfer Of Intellectual Property To Second Source Supplier, Term

+ References

No definition available.

+ Details

Name:	amag_ResearchAndDevelopmentAssetAcquiredOtherThanBusinessCombinationTransferOfIntellectualPropertyToSecondSourceSupplierTerm
Namespace Prefix:	amag_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Research And Development Asset Acquired Other Than Through Business Combination, Expiration Period

+ References

No definition available.

+ Details

Name:	amag_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationExpirationPeriod
Namespace Prefix:	amag_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Research and Development Asset Acquired Other Than Through Business Combination, Future Contingent Payments

+ References

No definition available.

+ Details

Name:	amag_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFutureContingentPayments
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Research And Development Asset Acquired Other Than Through Business Combination, Royalty Percentage

+ References

No definition available.

+ Details

Name:	amag_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationRoyaltyPercentage
Namespace Prefix:	amag_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Research And Development Asset Acquired Other Than Through Business Combination, Threshold For Future Contingent Payments

+ References

No definition available.

+ Details

Name:	amag_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationThresholdForFutureContingentPayments
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Research and Development Asset Acquired Other than Through Business Combination, Aggregate Research Reimbursement Expense

+ References

No definition available.

+ Details

Name:	amag_ResearchAndDevelopmentAssetAcquiredOtherthanThroughBusinessCombinationAggregateResearchReimbursementExpense
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Research And Development Asset Acquired Other than Through Business Combination, Period After Sale

+ References

No definition available.

+ Details

Name:	amag_ResearchAndDevelopmentAssetAcquiredOtherthanThroughBusinessCombinationPeriodAfterSale
Namespace Prefix:	amag_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Research and Development Asset Acquired Other Than Through Business Combination, Sales Milestone

+ References

No definition available.

+ Details

Name:	amag_ResearchandDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationSalesMilestone
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Research and Development Asset Acquired Other Than Through Business Combination, Sales Milestone Threshold

+ References

No definition available.

+ Details

Name:	amag_ResearchandDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationSalesMilestoneThreshold
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Research and Development Asset Acquired Other than Through Business Combination, Consideration Recorded

+ References

No definition available.

+ Details

Name:	amag_ResearchandDevelopmentAssetAcquiredOtherthanThroughBusinessCombinationConsiderationRecorded
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the payments due for sales milestones based upon the achievement of annual sales milestones.

+ References

No definition available.

+ Details

Name:	amag_SalesMilestonePaymentsBasedOnAchievementOfAnnualSalesMilestones
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the annual sales milestone targets that will require additional payments.

+ References

No definition available.

+ Details

Name:	amag_SalesMilestoneTargets
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Stock Issued During Period, Lock-Up Period

+ References

No definition available.

+ Details

Name:	amag_StockIssuedDuringPeriodLockUpPeriod
Namespace Prefix:	amag_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront payment made for the option to acquire the global rights to the DIF program.

+ References

No definition available.

+ Details

Name:	amag_UpfrontPaymentIssuedForOptionAgreement
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The minimum amount the entity agreed to spend under the long-term purchase commitment.

+ References

No definition available.

+ Details

Name:	us-gaap_LongTermPurchaseCommitmentAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=amag_OptionAgreementWithVeloBioToAcquireRightsToDifMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=amag_EndoceuticsLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationAnniversaryofClosingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationDeliverOfLaunchQuantitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationTieredRoyaltiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationFirstSalesMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=amag_EndoceuticsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationSecondSalesMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationThirdSalesMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	amag_IssuanceofStockLockUpPeriodAxis=amag_IssuanceofStockLockUpPeriodOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	amag_IssuanceofStockLockUpPeriodAxis=amag_IssuanceofStockLockUpPeriodTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=amag_PalatinLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationRegulatoryMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationRegulatoryMilestoneAchievementAcceptanceByU.S.FoodAndDrugAdministrationForNewDrugApplicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationRegulatoryMilestoneAchievementU.S.FoodAndDrugAdministrationApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration, License and Other Strategic Agreements (Details) - USD ($)		1 Months Ended		3 Months Ended		9 Months Ended
	Apr. 03, 2017	Feb. 28, 2017	Jul. 31, 2015	Jun. 30, 2017	Sep. 30, 2015	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Collaborative Agreements
Net shares issued in connection with license agreement, value						$ 12,555,000	$ 0
Finite-lived intangible assets						1,171,755,000		$ 1,094,100,000
Velo Bio option agreement
Collaborative Agreements
Upfront payment, option agreement					$ 10,000,000
Payments due			$ 65,000,000
Sales milestone payments based on annual sales milestones			$ 250,000,000
Covenant, royalty rate			0.00%
Increase of milestone payment when royalty rate is zero			50.00%
Minimum \| Velo Bio option agreement
Collaborative Agreements
Sales milestone targets			$ 100,000,000
Maximum \| Velo Bio option agreement
Collaborative Agreements
Sales milestone targets			$ 900,000,000
Endoceutics License Agreement
Collaborative Agreements
Upfront payment	$ 50,000,000
Number of shares issued under arrangement	600,000
Net shares issued in connection with license agreement, value	$ 13,500,000					$ 13,500,000
Consideration recorded				$ 83,500,000
IPR&D expense				5,800,000
Period after first commercial sale	10 years					10 years
Transfer of intellectual property to second source supplier, term (within)	2 years
Endoceutics License Agreement \| Research and Development Arrangement
Collaborative Agreements
Out-of-pocket expenses (up to)	$ 20,000,000.0
Endoceutics License Agreement \| Intrarosa developed technology
Collaborative Agreements
Finite-lived intangible assets				$ 77,700,000
Endoceutics License Agreement \| Anniversary of Closing
Collaborative Agreements
Maximum future contingent payments						$ 10,000,000
Endoceutics License Agreement \| Delivery of Launch Quantities
Collaborative Agreements
Maximum future contingent payments						10,000,000
Endoceutics License Agreement \| Tiered Royalties
Collaborative Agreements
Maximum future contingent payments	$ 150,000,000.0					$ 150,000,000.0
Royalty percentage, maximum	20.00%					20.00%
Net sales threshold, future contingent payments	$ 1,000,000,000.0					$ 1,000,000,000.0
Endoceutics License Agreement \| First Sales Milestone \| Endoceutics, Inc.
Collaborative Agreements
Sales milestone	15,000,000.0					15,000,000.0
Sales milestone, triggering amount	150,000,000.0					150,000,000.0
Endoceutics License Agreement \| Second Sales Milestone \| Endoceutics, Inc.
Collaborative Agreements
Sales milestone	30,000,000.0					30,000,000.0
Sales milestone, triggering amount	300,000,000.0					300,000,000.0
Endoceutics License Agreement \| Third Sales Milestone \| Endoceutics, Inc.
Collaborative Agreements
Sales milestone	850,000,000.0					850,000,000.0
Sales milestone, triggering amount	$ 500,000,000.0					500,000,000.0
Endoceutics License Agreement \| 180 Day Lock-Up Provision
Collaborative Agreements
Number of shares issued under arrangement	300,000
Stock issued, lock-up period	180 days
Endoceutics License Agreement \| One Year Lock-Up Provision
Collaborative Agreements
Number of shares issued under arrangement	300,000
Stock issued, lock-up period	1 year
Palatin License Agreement \| License Agreement Terms
Collaborative Agreements
Maximum future contingent payments						380,000,000.0
Upfront payment		$ 60,000,000
Maximum reimbursement		$ 25,000,000.0
Expiration period, following first commercial sale		10 years
Palatin License Agreement \| First Sales Milestone \| License Agreement Terms
Collaborative Agreements
Maximum future contingent payments		$ 300,000,000.0
Sales milestone		25,000,000.0
Sales milestone, triggering amount		250,000,000.0
Palatin License Agreement \| Regulatory milestone \| License Agreement Terms
Collaborative Agreements
Maximum future contingent payments		$ 80,000,000.0
Palatin License Agreement \| Regulatory milestone, acceptance by U.S. Food and Drug Administration for new drug application \| License Agreement Terms
Collaborative Agreements
Maximum future contingent payments						20,000,000
Palatin License Agreement \| Regulatory milestone, U.S. Food and Drug Administration approval \| License Agreement Terms
Collaborative Agreements
Maximum future contingent payments						$ 60,000,000